However, BRCC3-mutated AML1-ETO positive AML patients show favorable outcome, since BRCC3 inactivation may lead to an impaired capability of the BRCA1-A complex to repair DNA damage and subsequently higher sensitivity to DNA damaging chemotherapy [97]. The gene discussed is BRCC3; the disease is acute myeloid leukemia.